g12c

Adagrasib (MRTX849) is an orally active and selective covalent inhibitor of KRAS G12C. Adagrasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Adagrasib exhibits inhibitory activity against KRAS G12C mutant tumors.

Sotorasib (AMG-510) is an orally active and selective covalent inhibitor of KRAS G12C. Sotorasib binds to the GDP state of the inactive conformation of KRAS G12C and inhibits KRAS and its downstream signaling. Sotorasib exhibits inhibitory activity against KRAS G12C mutant tumors.

Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.

MRTX-1257 is a selective, irreversible, and covalent inhibitor of KRAS G12C with an IC50 of 900 pM for KRAS-dependent ERK phosphorylation in H358 cells. MRTX-1257 demonstrated 31% bioavailability in the mouse, with free fraction exposures well above cellular potency, and 77% target engagement in a PK/PD experiment.

ARS-853 is an inhibitor of K-RASG12C(IC50 : 2.5 μM), a mutant form of K-RAS that accumulates in the active GTP-bound state in certain cancer cells

KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.

KRas G12C inhibitor 1 is a compound that selectively inhibits the KRas G12C protein.

K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).

KRAS G12C Inhibitor 13 is a specific inhibitor targeting the KRAS G12C mutation.

KRAS G12C inhibitor 14 is a potent compound with an IC50 of 18 nM [1].

KRAS G12C inhibitor 15 is a potent inhibitor of the KRAS G12C protein.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

KRas G12C inhibitor 2 is a compound specifically designed to inhibit the KRas G12C mutation.

KRas G12C inhibitor 3 is a compound that specifically inhibits the KRas G12C mutation.

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 5 is a KRas G12C inhibitor. (Add a sentence that describes its primary function, mechanism, or application.)

KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.

KRAS G12C inhibitor 63 (K45) is a KRAS G12C inhibitor that can induce apoptosis and exhibits antitumor activity.

KRAS G12C Ligand-Linker Conjugates 1 are compounds formed by the conjugation of a KRASG12C ligand and a linker, utilized in the synthesis of PROTAC YF135.

KRAS G12C degrader-2 is an E3 ligase ligand-linker conjugate, incorporating a CRBN-based ligand and a linker, suitable for synthesizing PROTAC.

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C) mutant, achieving 100% protein modification at 10 μM after 24 hours in vitro.

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth [1].

KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.